The PennZone

  • Home
  • Entertainment
  • Marketing
  • Music
  • Non-profit
  • Books
  • Artificial Intelligence
  • Education
  • Automotive

Myonex Launches CTRx Europe, Central Pharmacy Network
The PennZone/10202189

Trending...
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • Slotozilla Reports Strong Growth in Q2 2026
HORSHAM, Pa.--(BUSINESS WIRE)--Myonex, a leading global clinical trial supply company, announces the launch of the first and only on-demand local drug sourcing in Europe. Built on a successful North American program, CTRx Europe offers significant benefits for trial sponsors, sites, and patients alike.

"With the growth of our CTRx service in North America, clients have been asking us to develop the same solution for them in Europe. Our new CTRx Europe solution is a game-changer for clinical sites in Europe," said James Lovett, Chief Executive Officer at Myonex. "Our solution will offer support for sites to source local drug for local patients, in individual European countries. Sponsors can remove overage and eliminate costs associated with up-front bulk comparator purchases, inventory management, and expired drugs. The program has delivered tremendous results in the United States and Canada, and we are pleased to be able to offer similar flexibility and savings in Europe."

More on The PennZone
  • Revenue Optics Launches Pricing and Revenue Growth Management Practice, Names Shafohi Alamgir Vice President
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
  • CasaPerks and CredHub Partner to Help the Multifamily Industry Strengthen Resident Activation Through Credit-Building Rewards
  • NaturismRE expands international research programme with Health & Wellbeing Survey
  • L2 Aviation and Gotonomi Extend UAV Connectivity Beyond Cellular Reach

Through its partnerships with central dispensing pharmacies in major European markets, Myonex can offer on-demand local sourcing. The CTRx solution provides sponsors with in-country local pricing and access to key oncology and other specialty medications and hospital lines. Sites need less storage space and fewer resources, so they can accommodate more trials. Sponsors can track dispensing via a secure, GDPR-compliant portal, and sites can request orders online.

Myonex's CTRx solution supports traditional, decentralized, and hybrid trials. In processes tailored to meet local regulations, both sponsor investigational medicinal products and commercial drugs, as well as ancillary items, can be delivered directly to the clinical site, central nursing center, a nurse, or even to the patient's home.

"The direct-to-patient offering makes adherence easier," said Samit Bhatt, Senior Director, Clinical Trial Patient Solutions, at Myonex. "And because our local partners serve local markets, logistics costs per patient and site shipment are lower, and sponsors can see significantly improved study start-up time."

More on The PennZone
  • LATO AI Solidifies Future in Pittsburgh with North Shore Headquarters
  • Re:InvestorHub Launches the First AI-Powered Operating System Built for Real Estate Investors
  • Nadi Plumbing Leads Charlotte in Private Fire Hydrant Services, Eyes Regional Expansion
  • Obsolete Industrial Expands Its Membership
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers

CTRx Europe is part of an end-to-end suite of clinical trial supply solutions from Myonex that also includes expanded packaging and labeling capabilities; warehousing, storage, and distribution; project management and more. For information, email globalsales@myonex.com.

About Myonex
Myonex
is a leading global clinical trial supply company with more than 30 years of experience supporting sponsors that range from Big Pharma to small biotech, as well as CROs, and other service providers. Its four unique services—sourcing, packaging/labeling, ancillaries and patient solutions—work together to create flexibility, improve effectiveness, increase efficiency and eliminate waste. The company problem-solves and tailors solutions to the specific requirements and complexities of each trial, and sponsors and CROs benefit from the simplicity of having a single vendor that can provide an optimized, integrated clinical trial supply strategy that saves time and money. Learn more at www.myonex.com.

Contacts

Maryanne Walsh
+1 267-307-0876
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • Slotozilla Reports Strong Growth in Q2 2026
  • Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
  • Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
  • Flexible Plan Investments Names Carl Resnick President
  • Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
  • Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
  • No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
  • The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
  • Sharon Pinkenson Chosen as Philly Girl Top 40 Winner
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
  • San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
  • Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
  • GGILabs Expands Local SEO Services to Help Businesses Compete in AI-Driven Search
  • Sara Viteri, Turnstone Creative Senior Producer, Named to Lehigh Valley Business' Forty Under 40
  • Boyertown Mechanic Travels to Nashville to Learn How AI Is Changing Auto Repair

Popular on PennZone

  • Heritage at South Brunswick Introduces New Ferndale Floorplan: The Largest Single-Family Home Design in the Community - 715
  • Omnitronics launches Ecosystem Health Dashboard to enable proactive monitoring across dispatch environments - 108
  • Leeds Billboard Campaign Drives 188% Traffic Uplift as AI Enquiries Rise 266% for Loud! OOH - 103
  • Sister Files Lawsuit Against Georgia Funeral Home for Alleged Mishandling of Brother's Remains
  • Boston Industrial Solutions, Inc. Introduces SAP-G70 Primer for bonding silicone to silicone and other materials
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Board of Directors
  • AI, Drones, Defense & Explosive Growth: Why ZenaTech Is Emerging as One of the Most Compelling Technology Growth Stories (N A S D A Q: ZENA)
  • $40 Billion Global Market Value by 2030 Projected in Unmanned Aerial Vehicle or Other Drone Technology Sector, Growing at 9.2% Compound Annual Growth
  • Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
  • Crossroads4Hope Announces The Lipschutz Women's Fund

Similar on PennZone

  • New Analysis Details Three Converging Forces in AI and Workforce Policy Behind a $37 Billion GDP Reduction
  • Popular AI planner Voiset launches version 2.0 and enters MENA at LEAP 2026 with full Arabic support
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
  • Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
  • Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
  • Slotozilla Reports Strong Growth in Q2 2026
  • Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
  • FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us